HC Wainwright & Co. Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $54
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.
HC Wainwright & Co. analyst Douglas Tsao maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $52 to $54.